Cerebrovascular disease is the general term for cerebrovascular diseases caused by various causes. Stroke is the main clinical type of cerebrovascular disease, including ischemic stroke and hemorrhagic stroke. Stroke is one of the major diseases that endanger the health and life of middle-aged and elderly people. In the third national survey on causes of death published by the Ministry of Health in 2008, stroke has overtaken malignant tumors as the number one cause of death in China, and the high morbidity, mortality and disability rates of this disease bring heavy burden and pain to the society and families. Ischemic stroke is cerebral infarction, also known as cerebral thrombosis and cerebral infarction. It is a clinical syndrome in which the blood supply to the brain is impaired due to various causes, resulting in ischemic and hypoxic necrosis of local brain tissue and corresponding neurological deficits, and cerebral infarction is the most common type of stroke, accounting for about 70%-80%. According to TOAST typing, it can be divided into ①: large artery atherosclerosis type. ②: Cardiogenic embolism. ③: Small artery occlusion type. ④: Other etiology type. ⑤: unexplained type. The main risk factors for ischemic stroke include: hypertension, smoking, diabetes, dyslipidemia, atrial fibrillation, heart valve disease, endocardial disease, cardiomyopathy, asymptomatic carotid stenosis, and obesity; there are also non-interventional risk factors: age, gender, genetics, race, and low birth weight. The common clinical manifestations of ischemic stroke include sudden onset of unfavorable speech, weakness or numbness of the lateral limbs, slanting of the mouth, double vision, choking on water, and dizziness. The key to early treatment of ischemic stroke is revascularization, which is fundamental to the treatment, and since 1995, several relevant clinical trials have established the era of standard intravenous thrombolysis represented by recombinant fibrinogen activator (rt-PA). Thrombolysis is recommended as the highest level of acute ischemic stroke in all national guidelines, but the rate of thrombolysis in China is extremely low for various reasons, far from the international average of thrombolysis rate. Our department has accumulated some experience in intravenous thrombolytic therapy, and I will introduce the process of thrombolytic therapy and the factors affecting the rate and effect of thrombolysis that we encountered in our clinical work, hoping that patients and their families can understand ischemic stroke and intravenous thrombolytic therapy more easily and deeply, and face the disease more positively, so that together with medical workers, we can contribute to relieving the pain and improving the quality of life of patients. We hope that the patients and their families will have a better understanding of ischemic stroke and intravenous thrombolysis, and face the disease more positively.